VECTIBIX (Panitumumab)-100mg

Vectibix is classified as a “monoclonal antibody” and “signal transduction inhibitor” by binding to epidermal growth factor receptors (EGFR). It is designed to block growth signals from getting to EGFR on both cancer cells and normal cells. In cancer cells, this blockage may help prevent these cells from growing and surviving.

Panitumumab is for treating patients with wild-type RAS metastatic colorectal cancer (cancer that has spread outside of the colon and rectum). Wild-type RAS is a cancer without mutations in the KRAS and NRAS genes. Vectibix can be used as a first-time treatment given with chemotherapy called FOLFOX (folinic acid, fluorouracil, oxaliplatin) Alone, following disease progression with the following chemotherapies: fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy